Want to see GB:STX full AI Analyst Report?
STX Stock Chart & Stats
9.85 p
-0.05 p(-1.87%)
At close: 4:00 PM EST
9.85 p
-0.05 p(-1.87%)
Day’s Range― - ―
52-Week Range2.70 p - 12.50 p
Previous CloseN/A
Volume699.61K
Average Volume (3M)3.16M
Market Cap
£65.78M
Enterprise Value109.63M
Total Cash (Recent Filing)£11.63M
Total Debt (Recent Filing)£30.15M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Sep 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,069,524,200
10 Day Avg. Volume1,665,963
30 Day Avg. Volume3,163,002
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)-5.76
Price to Sales (P/S)1.71
P/FCF Ratio-9.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£76.00M
Bulls Say, Bears Say
Bulls Say
Cash Flow$6.5m of cash plus successful $10m raise with AOP Health does provide some much-needed breathing room for Shield in 2025.
Prescription CoverageThe percentage of non-covered prescriptions dropped from 37% to 22%, contributing to the revenue growth.
Revenue GrowthThe significant increase in NSP in 4Q24 to $237 supported Shield delivering $32.2m in revenues for 2024, slightly ahead of expectations.
Bears Say
Cash Flow TimingThe timing at which Shield becomes cash flow positive may be delayed beyond 2025, with negative script growth being a concern.
Script GrowthNegative script growth in Q4 and a potentially soft 1Q25 driven by usual insurance renewals and unwind of year-end stocking is a concern.
Shield Therapeutics News
STX FAQ
What was Shield Therapeutics PLC’s price range in the past 12 months?
Shield Therapeutics PLC lowest share price was 2.70 p and its highest was 12.50 p in the past 12 months.
What is Shield Therapeutics PLC’s market cap?
Shield Therapeutics PLC’s market cap is £65.78M.
When is Shield Therapeutics PLC’s upcoming earnings report date?
Shield Therapeutics PLC’s upcoming earnings report date is Sep 03, 2026 which is in 59 days.
How were Shield Therapeutics PLC’s earnings last quarter?
Shield Therapeutics PLC released its earnings results on Apr 09, 2026. The company reported -0.006 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.006 p.
Is Shield Therapeutics PLC overvalued?
According to Wall Street analysts Shield Therapeutics PLC’s price is currently Overvalued.
Does Shield Therapeutics PLC pay dividends?
Shield Therapeutics PLC does not currently pay dividends.
What is Shield Therapeutics PLC’s EPS estimate?
Shield Therapeutics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shield Therapeutics PLC have?
Shield Therapeutics PLC has 1,069,524,200 shares outstanding.
What happened to Shield Therapeutics PLC’s price movement after its last earnings report?
Shield Therapeutics PLC reported an EPS of -0.006 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.299%.
Which hedge fund is a major shareholder of Shield Therapeutics PLC?
Currently, no hedge funds are holding shares in GB:STX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shield Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.21%
12-Months-Change
Fundamentals
Return on Equity
121.87%
Trailing 12-Months
Asset Growth
5.64%
Trailing 12-Months
Company Description
Shield Therapeutics PLC
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.